Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy

Loading news article.

Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy | WAPE

Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy

Article summary

Related companies

Comments —